Madam,

We read with interest the recently published review article by Patel *et al.* titled "Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis."\[[@ref1]\] Tanezumab is under investigation for the treatment of osteoarthritis pain and chronic low back pain by Pfizer Inc. and Eli Lilly & Company. As Pfizer or Lilly were not involved or consulted regarding the content of this article, we would like to point out that the molecular formula of tanezumab presented in Figure 1 is incorrect. For a more accurate representation of the structure of tanezumab, we refer readers to an article by La Porte *et al.*\[[@ref2]\]

---On behalf of the tanezumab development team.
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